Fresh Tracks Therapeutics Statistics
Share Statistics
Fresh Tracks Therapeutics has 5.97M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 5.97M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 806 |
| FTD / Avg. Volume | 30.23% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.91 and the forward
PE ratio is null.
Fresh Tracks Therapeutics's PEG ratio is
0.01.
| PE Ratio | -0.91 |
| Forward PE | n/a |
| PS Ratio | 0.65 |
| Forward PS | 0.3 |
| PB Ratio | 0.52 |
| P/FCF Ratio | -1.2 |
| PEG Ratio | 0.01 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Fresh Tracks Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.98,
with a Debt / Equity ratio of 0.
| Current Ratio | 6.98 |
| Quick Ratio | 6.98 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1272 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $2,001,500 |
| Profits Per Employee | $-1,423,500 |
| Employee Count | 4 |
| Asset Turnover | 0.69 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 1.08% in the
last 52 weeks. The beta is 1.17, so Fresh Tracks Therapeutics's
price volatility has been higher than the market average.
| Beta | 1.17 |
| 52-Week Price Change | 1.08% |
| 50-Day Moving Average | 0.81 |
| 200-Day Moving Average | 0.82 |
| Relative Strength Index (RSI) | 76.87 |
| Average Volume (20 Days) | 2,666 |
Income Statement
In the last 12 months, Fresh Tracks Therapeutics had revenue of 8.01M
and earned -5.69M
in profits. Earnings per share was -0.96.
| Revenue | 8.01M |
| Gross Profit | 8.01M |
| Operating Income | -6.36M |
| Net Income | -5.69M |
| EBITDA | -5.65M |
| EBIT | -5.69M |
| Earnings Per Share (EPS) | -0.96 |
Full Income StatementBalance Sheet
The company has 10.87M in cash and 0 in
debt, giving a net cash position of 10.87M.
| Cash & Cash Equivalents | 10.87M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -172.16M |
| Total Assets | 11.59M |
| Working Capital | 9.9M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -4.34M
and capital expenditures 0, giving a free cash flow of -4.34M.
| Operating Cash Flow | -4.34M |
| Capital Expenditures | n/a |
| Free Cash Flow | -4.34M |
| FCF Per Share | -0.73 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of -79.44% and -71.12%.
| Gross Margin | 100% |
| Operating Margin | -79.44% |
| Pretax Margin | -71.12% |
| Profit Margin | -71.12% |
| EBITDA Margin | -70.55% |
| EBIT Margin | -79.44% |
| FCF Margin | -54.25% |
